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second to hypertensive heart disease (HLVH) using 2D speckle tracking
imaging.
Methods: 2D fort chamber long-axis and basal, middle, and apical
short-axis of LV images were acquired in 97patients with LVH including
67 with HCM and 30 with HLVH, and in 30 age-matched controls. Radial
strain, longitudinal strain, time interval from the R-wave to peak radial
strain (Trs), and time to peak longitudinal strain (Tls) were measured in
six equidistant segments at each level of the 3 LV short-axis and 4C long-
axis views using 2D speckle tracking analysis. To assess LV dys-
synchrony, Trs (rs)-18SD, the standard deviation (SD) of Tls (ls) was
calculated.
Results: Regional radial strain in the middle and apical short-axis seg-
ments was significantly less in patients with HCM than in those with HHD
(56%±23 VS 45%±21 and 47%±19 VS 38%±17respectevely, p<0.01 ).
Regional longitudinal basal strain was also less in HCM (–13±3.3% VS –17±
2.9%, p=0.002). Trs-18SD and Tls were significantly longer in patients with
HCM than in age-matched controls and patients with HLVH (Trs-18SD:
HCM: 68±22ms, HHD: 21±11ms, control: 15±12ms P < 0.001, Tls – : HCM:
7 – ±12ms, HHD: 44±11ms, control: 33±13ms P < 0.001).
Conclusions: The presence of LVH is thus not always associated with LV
dyssynchrony. However, the greater reduction of regional strain and severe
LV dyssynchrony in HCM may contribute to the adverse cardiovascular out-
comes associated with this disease. 
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Background: Breast cancer is the most frequent female cancer. Treat-
ment of HER2+ tumours evolved with immunotherapy, leading to
improved survival. Cardiac toxicity associated to trastuzumab is frequent
but reversible in 75% of cases. However, only little is know about the
cardiotoxicity of new anti-VEGF antibodies associated to trastuzumab. In
this study, we aimed to assess the cardiac tolerance of bevacizumab asso-
ciated with trastuzumab and chemotherapy in HER2+ breast cancer
patients. 
Methods and results: This is a post-hoc analysis of the BEVERLY-2
study, aiming to assess the efficacy of neoadjuvant bevacizumab, trastu-
zumab, and chemotherapy for primary inflammatory HER2+ breast cancer.
A cohort of 52 patients was prospectively included. Left ventricular ejection
fraction (LVEF) was assessed by echocardiography and/or isotopic ventric-
ulography every three months during the mean follow-up of 33±3,42
months. Mean age prior to chemotherapy was 49,75 years ±11,60. On inclu-
sion, mean LVEF was 66,56±6,13.There was no significant difference
between LVEF on inclusion and before the 5th cycle of chemotherapy fifth
cycle (C5)(66,56%±6,13 vs 65,11%±7,68 ; p=0,24) ,whereas LVEF was sig-
nificantly reduced at the end of the neoadjuvant therapy (62,07%±7,84 vs
66,56±6,13; p=0,0001). The nadir of LVEF was 57,87%±8,79 and occured
generally during the adjuvant period. In 16 patients, LVEF decreased below
50% after neoadjuvant therapy but complete recovery of LVEF was
observed in all at the end of the follow-up, 3 months after the end of the
treatment (Figure 1, next page). 
Conclusion: In this study, with an effective treatment protocol for inflam-
matory breast cancer, reduction in LVEF was observed in 30% of patients,
however, it was reversible in all. Nadir of LVEF was observed after the final
adjuvant therapy (31%). This timing and the possibility of recovery should be
considered when discussing the interruption of chemotherapy because of
reduced LVEF during the follow up. 
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Hereditary heart diseases are typically characterized by autosomal domi-
nant inheritance and delayed cardiac expression. Predictive genetic testing is
offered to asymptomatic relatives to allow targeted medical care with early
therapeutics in order to reduce the risk of complications (sudden death, heart
failure). Psychological and sociological issues related to predictive testing are
however complex and have been poorly studied. Predictive genetic testing is
performed in our multidisciplinary out-patient clinic dedicated to cardio-
genetics since 1999. 
To evaluate our practices regarding predictive genetic testing for hereditary
heart diseases and study the behavior of relatives after pre-test consultation
(information phase), especially regarding a waiting period that was offered
before blood sampling. 
We retrospectively studied records from 304 consecutive relatives seen in
our department and have requested predictive genetic testing. Underlying
diseases in the families were HCM (60%), DCM (17%), ARVC (15%), LQT
(5%), Brugada syndrome (2%) and other (1%). A total of 21 different genes
were analyzed and most frequent ones were MYBPC3 (97), MYH7 (77),
LMNA (37), PKP2 (29) and TNNT2 (16). There were 260 adults and
44 minors. At the time of the first consultation, the average age was 37 years,
and 83% of the relatives previously had a cardiac checkup (echocardiography
for 71%). 
After first multidisciplinary consultation, 22 relatives (8%) dropped out of
procedure (did not performed blood sampling) and 11 relatives (3%) per-
formed blood sampling but did not come back to know their results. Blood
sample was delayed for 70% of relatives and immediate for 30%. A mutation
was present in 36% of relatives (leading to careful follow-up and cascade
screening in offspring) and absent in 64% (they were reassured and discharged
from clinic).
We observed a high level of genetic uptake after initial consultation but a
minority of relatives decided to stop or delay the procedure. These results sug-
gest the benefit of a waiting period before blood sampling and illustrate the
importance of a multidisciplinary team in this setting. 
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This study assessed the long-term outcome of heart (HTx) and heart-lung
transplantation (HLTx) in patients with congenital heart disease (CHD) and
children with non-congenital cardiac or pulmonary disease.
Methods: Retrospective single-centre analysis of long-term posttransplant
outcome, with chart collection of clinical and paraclinical data.
Results: From 1984 to 2013, 111 first-HTx, 5 HLTx and 6 re-HTx
were performed (62males), in patients aged 11.7±8.2y: 96(79%) aged
<18y. Cardiopathy included 61 cardiomyopathies (50.8%), 50 CHD
(41.7%), 6 retransplants (5%). HLTx included 1 Eisenmenger, 1 PPHT,
and 2 pulmonary diseases. Patients with cardiomyopathy were younger
than CHD (8.7y vs 14.9y).Seventeen (14%) patients had circulatory
mechanical support as bridge to transplant. Acute rejection occurred more
frequently within the first year post-transplant or > 5thyear in non-com-
pliant teenagers. Overall 33 patients died (27%), 3.5±4.6y postTx (1 day
